Amgen Reports Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen announced positive topline results from a Phase 3 study of its drug candidate, dazodalibep, for treating moderate-to-severe systemic Sjögren's disease. The drug, acquired through Amgen's buyout of Horizon Therapeutics, has shown promising efficacy in this patient population.
The results mark a significant milestone for Amgen as it continues to expand its portfolio in autoimmune diseases. Dazodalibep's success in this trial could pave the way for its approval and subsequent market introduction, enhancing treatment options for patients suffering from this condition.
Sources
Every quote below is verbatim from the article it is attributed to.
“AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE”
SEC Filing — AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE“<figure><div><img”
biopharma dive — Amgen reports a Phase 3 win with Sjögren’s drug candidate